Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 636

1.

Influence of Vitamin D Receptor Gene Polymorphisms on Response to Pegylated Interferon in Chronic Hepatitis B Egyptian Patients.

Mostafa-Hedeab G, Sabry D, Abdelaziz GM, Ewaiss M, Adli N, Fathy W.

Rep Biochem Mol Biol. 2018 Apr;6(2):186-196.

2.
3.

Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?

Moreno-Cubero E, Del Arco RTS, Peña-Asensio J, de Villalobos ES, Míquel J, Larrubia JR.

World J Gastroenterol. 2018 May 7;24(17):1825-1838. doi: 10.3748/wjg.v24.i17.1825. Review.

4.

RFX1 participates in doxorubicin-induced hepatitis B virus reactivation.

Wang J, Jia J, Chen R, Ding S, Xu Q, Zhang T, Chen X, Liu S, Lu F.

Cancer Med. 2018 May;7(5):2021-2033. doi: 10.1002/cam4.1468. Epub 2018 Mar 30.

5.

Increasing co-morbidities in chronic hepatitis B patients: experience in primary care and referral practices during 2000-2015.

Liu A, Le A, Zhang J, Wong C, Wong C, Henry L, Nguyen MH.

Clin Transl Gastroenterol. 2018 Mar 14;9(3):141. doi: 10.1038/s41424-018-0007-6.

6.

Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management.

Cannizzaro MV, Franceschini C, Esposito M, Bianchi L, Giunta A.

Psoriasis (Auckl). 2017 Apr 15;7:35-40. doi: 10.2147/PTT.S108209. eCollection 2017. Review.

7.

Durability of Telbivudine-Associated Improvement of Renal Function Following Withdrawal or Switching of Antivirals in Chronic Hepatitis B Patients.

Hsu CW, Chen YC, Chang ML, Lin CC, Lin SM, Chen WT, Chu YD, Yeh CT.

Open Forum Infect Dis. 2017 Dec 22;5(1):ofx271. doi: 10.1093/ofid/ofx271. eCollection 2018 Jan.

8.

Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients.

Lee HJ, Kim SJ, Kweon YO, Park SY, Heo J, Woo HY, Hwang JS, Chung WJ, Lee CH, Kim BS, Suh JI, Tak WY, Jang BK.

PLoS One. 2018 Jan 12;13(1):e0190581. doi: 10.1371/journal.pone.0190581. eCollection 2018.

9.

Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon?

Alonso S, Guerra AR, Carreira L, Ferrer JÁ, Gutiérrez ML, Fernandez-Rodriguez CM.

BMC Gastroenterol. 2017 Dec 21;17(1):168. doi: 10.1186/s12876-017-0726-2. Review.

10.

Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon-α treatment in HBeAg-positive chronic hepatitis B patients.

Zhu MY, Chen PZ, Li J, Yu DM, Huang D, Zhu XJ, Han Y, Chen J, Huang W, Chen YY, Gong QM, Jiang JH, Zhang DH, Zhang Y, Zhang JM, Zhang XX.

J Med Virol. 2018 Apr;90(4):721-729. doi: 10.1002/jmv.25010. Epub 2018 Jan 12.

11.

Development and validation of a model for staging hepatic fibrosis for chronic hepatitis B patients with E antigen-positive.

Wang H, Zhou Y, Yan R, Ru GQ, Yu LL, Wang MS, Chen MJ.

Oncotarget. 2017 Oct 24;8(58):98812-98822. doi: 10.18632/oncotarget.22003. eCollection 2017 Nov 17.

12.

Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update).

Hou J, Wang G, Wang F, Cheng J, Ren H, Zhuang H, Sun J, Li L, Li J, Meng Q, Zhao J, Duan Z, Jia J, Tang H, Sheng J, Peng J, Lu F, Xie Q, Wei L; Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association.

J Clin Transl Hepatol. 2017 Dec 28;5(4):297-318. doi: 10.14218/JCTH.2016.00019. Epub 2017 Nov 12. No abstract available.

13.

Time-varying serum gradient of hepatitis B surface antigen predicts risk of relapses after off-NA therapy.

Chien NH, Huang YT, Wu CY, Chang CY, Wu MS, Kao JH, Mo LR, Tai CM, Lin CW, Yang TH, Lin JT, Hsu YC.

BMC Gastroenterol. 2017 Dec 8;17(1):154. doi: 10.1186/s12876-017-0697-3.

14.

Antiviral Efficacy of Tenofovir Monotherapy in Children with Nucleos(t)ide-naive Chronic Hepatitis B.

Choe JY, Ko JS, Choe BH, Kim JE, Kang B, Lee KJ, Yang HR.

J Korean Med Sci. 2018 Jan 8;33(2):e11. doi: 10.3346/jkms.2018.33.e11.

15.

A robust cell culture system supporting the complete life cycle of hepatitis B virus.

Michailidis E, Pabon J, Xiang K, Park P, Ramanan V, Hoffmann HH, Schneider WM, Bhatia SN, de Jong YP, Shlomai A, Rice CM.

Sci Rep. 2017 Nov 30;7(1):16616. doi: 10.1038/s41598-017-16882-5.

16.

Current Condition of Chronic Hepatitis B Virus Infection in Cuban Adults.

Marlen Ivón CF, Zaily DG, Conde-Eduardo Leda Patricia DS, Enrique GG, Enrique AS, Yadina MP.

Curr Ther Res Clin Exp. 2017 May 4;85:15-19. doi: 10.1016/j.curtheres.2017.04.007. eCollection 2017.

17.

Value of gamma-glutamyltranspeptidase-to-platelet ratio in diagnosis of hepatic fibrosis in patients with chronic hepatitis B.

Hu YC, Liu H, Liu XY, Ma LN, Guan YH, Luo X, Ding XC.

World J Gastroenterol. 2017 Nov 7;23(41):7425-7432. doi: 10.3748/wjg.v23.i41.7425.

18.

Obstetricians' and gynecologists' knowledge, education, and practices regarding chronic hepatitis B in pregnancy.

Niu B, Marzio DH, Fenkel JM, Herrine SK.

Ann Gastroenterol. 2017;30(6):670-674. doi: 10.20524/aog.2017.0196. Epub 2017 Sep 30.

19.

Serum Levels of M2BPGi as Short-Term Predictors of Hepatocellular Carcinoma in Untreated Chronic Hepatitis B Patients.

Liu J, Hu HH, Lee MH, Korenaga M, Jen CL, Batrla-Utermann R, Lu SN, Wang LY, Mizokami M, Chen CJ, Yang HI.

Sci Rep. 2017 Oct 30;7(1):14352. doi: 10.1038/s41598-017-14747-5.

20.

Comparison of the efficacy of Gd-EOB-DTPA-enhanced magnetic resonance imaging and magnetic resonance elastography in the detection and staging of hepatic fibrosis.

Wu WP, Hoi CI, Chen RC, Lin CP, Chou CT.

Medicine (Baltimore). 2017 Oct;96(42):e8339. doi: 10.1097/MD.0000000000008339.

Supplemental Content

Support Center